logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Latigo Biotherapeutics Appoints Neil Singla, M.D. As Chief Medical Officer

Aug 19, 2024•over 1 year ago

Position

Chief Medical Officer

Company

Latigo Biotherapeutics

Neil Singla
Thousand OaksBiotechnology

Description

Latigo Biotherapeutics Inc. announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. The company also appointed world-renowned analgesic scientist Neil Singla, M.D., as chief medical officer.

Company Information

Company

Latigo Biotherapeutics

Location

Thousand Oaks, California, United States

About

Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months